An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
NCT03137160 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4
Last updated 2024-02-23
Summary
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Conditions
- Pyoderma Gangrenosum
Interventions
- BIOLOGICAL
-
Ixekizumab
Injection
Sponsors & Collaborators
- collaborator INDUSTRY
-
Ohio State University
lead OTHER
Principal Investigators
-
Benjamin Kaffenberger, MD · Dermatologist
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-05-04
- Primary Completion
- 2018-08-16
- Completion
- 2018-08-16
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
NCT03971643 ·Status: COMPLETED ·Phase: PHASE2
-
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
NCT02318914 ·Status: TERMINATED ·Phase: PHASE3
-
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
NCT03485976 ·Status: COMPLETED ·Phase: PHASE2
-
Spesolimab in Pyoderma Gangrenosum
NCT06092216 ·Status: TERMINATED ·Phase: PHASE2
-
Gene Therapy for Chronic Granulomatous Disease
NCT00394316 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa
NCT01704534 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Infliximab for the Treatment of Pemphigus Vulgaris
NCT00283712 ·Status: COMPLETED ·Phase: PHASE2
-
Anakinra for Inflammatory Pustular Skin Diseases
NCT01794117 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
NCT03075904 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
NCT06136403 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease
NCT02234934 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
NCT02226146 ·Status: COMPLETED ·Phase: PHASE2
-
Deucravacitinib in PG
NCT05821374 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)
NCT01855685 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
NCT07113743 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
NCT05593445 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
NCT05681481 ·Status: TERMINATED ·Phase: PHASE3
-
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
NCT05964413 ·Status: TERMINATED ·Phase: PHASE3
-
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
NCT04186559 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
NCT00001761 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
NCT02704429 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
NCT00134134 ·Status: COMPLETED ·Phase: PHASE1
-
The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
NCT04465292 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
NCT00472030 ·Status: COMPLETED ·Phase: PHASE4
-
Etanercept in Hidradenitis Suppurativa
NCT00329823 ·Status: COMPLETED ·Phase: PHASE2